# Mayo Clinic Breast Cancer SPORE

> **NIH NIH P50** · MAYO CLINIC ROCHESTER · 2020 · $2,318,378

## Abstract

Program Summary/Abstract
This second renewal application of the Mayo Clinic Breast Cancer SPORE is being submitted with the vision
that the burden of breast cancer can be reduced through the performance of innovative translational research
addressing issues of high significance for women. The science of the SPORE includes four translational
research projects. Project 1: “Cancer risks for mutations in breast cancer predisposition genes” focuses on
non-BRCA1/BRCA2 genes included in “panel based” tests. Using the PROMPT registry, the investigators will
define the penetrance of breast cancers associated with inactivating mutations, the clinical relevance of
variants of uncertain significance, and pathological “phenotype” of these mutations. Project 2: “Therapeutic
targeting of ERβ in triple negative breast cancer (TNBC)” is based on Mayo investigator data that ERβ, when
expressed in TNBC, is prognostic, and that ERβ agonists suppress proliferation through the TGFβ pathway.
This project culminates in a phase II study of estradiol in ERβ+TNBC within the Translational Breast Cancer
Research Symposium. Project 3: “Measles virus based immunovirotherapy in the treatment of metastatic
breast cancer” is based on pioneering work of Mayo investigators to develop a measles virus (MV) that expresses
an immunostimulatory transgene (MV-NAP), and the synergistic antitumor activity of MV-NAP with PD-1 blockade.
This project includes a MV-NAP phase I study, and development of additional preclinical data that will inform
the clinical trial of the combination of MV-NAP and PD-1 blockade. Project 4: “Pharmacogenomics of
aromatase inhibitors (AI) in early stage postmenopausal breast cancer” is based upon the importance of
estrogen levels in AI-treated women. The investigators plan secondary analyses of adjuvant AI trials to
determine whether inadequate estrogen suppression is associated with cancer recurrence, followed by a
genome-wide analysis to identify genetic variants associated with the “optimal” estrogen threshold and then
prospective validation in a clinical study. These research projects are supported by three highly interactive
cores: Core A: Administrative Core, Core B: Biospecimen and Pathology Core, and Core C: Biostatistics,
Bioinformatics, and Patient Registry Core. A Developmental Research Program will continue to identify and
develop research projects that hold the greatest promise to advance to full SPORE projects, and a Career
Enhancement Program will continue to identify and support faculty investigators in breast cancer translational
research that have the greatest potential to become future SPORE leaders. The investigators, cores, and the
research programs in the SPORE are all integrated in the Mayo Clinic Cancer Center. Collectively, our SPORE
will make discoveries and translate them into the clinic for the benefit of women with, or at risk of breast
cancer.

## Key facts

- **NIH application ID:** 10017877
- **Project number:** 5P50CA116201-15
- **Recipient organization:** MAYO CLINIC ROCHESTER
- **Principal Investigator:** MATTHEW Philip GOETZ
- **Activity code:** P50 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $2,318,378
- **Award type:** 5
- **Project period:** 2005-09-22 → 2022-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10017877

## Citation

> US National Institutes of Health, RePORTER application 10017877, Mayo Clinic Breast Cancer SPORE (5P50CA116201-15). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10017877. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*